Form4insider filings, from the source

SEC Form 4 · accession 0001567619-18-003758

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Joshua H. Bilenker
Officer — President & CEO · Director
Period of report
Oct 3, 2018
Accepted (ET)
Oct 5, 2018 · 4:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockOct 3, 2001M10,000$3.648A145,407D
Common StockF2,F3Oct 3, 2001S2,905$165.0058D142,502D
Common StockF1,F2,F4Oct 3, 2018S1,225$165.9477D141,277D
Common StockF2,F5Oct 3, 2018S673$167.0908D140,604D
Common StockF2,F6Oct 3, 2018S1,297$168.2902D139,307D
Common StockF2,F7Oct 3, 2018S3,705$169.003D135,602D
Common StockF2,F8Oct 3, 2018S195$169.6779D135,407D
Common StockOct 4, 2018M10,000$3.648A145,407D
Common StockF2,F9Oct 4, 2018S1,700$160.6138D143,707D
Common StockF2,F10Oct 4, 2018S1,553$161.4096D142,154D
Common StockF2,F11Oct 4, 2018S3,152$162.6041D139,002D
Common StockF2,F12Oct 4, 2018S2,000$163.6428D137,002D
Common StockF2,F13Oct 4, 2018S1,395$164.5921D135,607D
Common StockF2,F14Oct 4, 2018S200$165.5689D135,407D
Common Stockholding———30,000IBy Joshua H. Bilenker, ttee Joshua Bilenker 2018 GRAT, dated 06/20/2018

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (Right to Buy)F15$3.648Oct 3, 2018M10,000D—Jun 18, 2024Common Stock10,00082,985D
Employee Stock Option (Right to Buy)F15$3.648Oct 4, 2018M10,000D—Jun 18, 2024Common Stock10,00072,985D

Explanation of responses